AIRNA Bio

AIRNA is a biotechnology company pioneering the development of RNA editing therapeutics through its proprietary RESTORE+ platform. The company utilizes the body's endogenous ADAR (Adenosine Deaminase Acting on RNA) enzymes to perform precise, single-nucleotide edits on mRNA, aiming to treat both rare and common diseases. Its lead program is focused on Alpha-1 Antitrypsin Deficiency (AATD), designed to correct the underlying genetic mutation and restore healthy protein function. By targeting RNA rather than DNA, AIRNA's approach offers a potentially safer, reversible, and more titratable alternative to permanent gene editing. The company is backed by leading life science investors and maintains operations in Cambridge, Massachusetts, and Tübingen, Germany.